Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04332588 · ClinicalTrials.gov registry record · Phase 1

Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI

A Phase 1 study of HER2-positive Breast Cancer, sponsored by University of Alabama at Birmingham.

Recruiting
Registry status
Phase 1
Development phase
25
Enrollment target
1
Study location

NCT04332588 is a Phase 1 study of HER2-positive Breast Cancer that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 25 participants, below the 239-participant average among 54 other HER2-positive Breast Cancer trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04332588, a Phase 1 study of HER2-positive Breast Cancer, is actively recruiting participants, sponsored by University of Alabama at Birmingham.

RECRUITING
Registry status
Phase 1
Development phase
25 participants
Enrollment target
1
Study location

Study Summary

The purpose of the study is to see if using an investigational drug called \[18F\]FMISO with PET/MRI imaging can help monitor and predict the effect of trastuzumab (Herceptin) on chemotherapy in patients diagnosed with advanced HER2 positive breast cancer. This study is for imaging purposes only and is not a treatment study. The results of this study will not change a patient's clinical treatment plan but it may help physicians and researchers better understand how best to treat patients with breast cancer in the future.

Conditions Studied

HER2-positive Breast Cancer

Interventions

  • DRUG [18F]FMISO PET/MRI imaging

Study Locations (1)

Alabama

  • The University of Alabama at Birmingham - Birmingham

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2022-03-25
Est. Completion 2027-08
Phase Phase 1

Sponsor

University of Alabama at Birmingham

1,160 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04332588

The ClinicalTrials.gov registry entry for NCT04332588 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 239-participant average among 54 other HER2-positive Breast Cancer trials with a reported enrollment target (90% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HER2-positive Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which [18F]FMISO PET/MRI imaging is the first listed.

NCT04332588 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.

Frequently Asked Questions

What is clinical trial NCT04332588 about?

NCT04332588 is a clinical study titled "Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI". The purpose of the study is to see if using an investigational drug called \[18F\]FMISO with PET/MRI imaging can help monitor and predict the effect of trastuzumab (Herceptin) on chemotherapy in patients diagnosed with advanced HER2 positive breast cancer. This study is for imaging purposes only and...

What is the current status of trial NCT04332588?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2022-03-25. Estimated completion is 2027-08.

What conditions does trial NCT04332588 study?

This clinical trial studies the following conditions: HER2-positive Breast Cancer.

What interventions are being tested in trial NCT04332588?

The interventions under investigation include: [18F]FMISO PET/MRI imaging (DRUG).

Who is sponsoring clinical trial NCT04332588?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04332588 being conducted?

This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HER2-positive Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

HER2-positive Breast Cancer

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.